This synthetic sequence has become a focus in peptide research
There is already strong public interest in oral weight loss treatment before these medications have even officially launched in the UK
PMID: 30141373
It is important to note that if ED develops or worsens during GLP-1 therapy, this is more likely related to the underlying conditions being treated (diabetes, obesity, cardiovascular disease) or other concurrent factors rather than the medication itself
By Brand On the basis of brand, the Glucagon-Like Peptide 1 (GLP-1) Agonists Market is segmented into Byetta, Bydureon, Victoza, Trulicity, and Lyxumia
However, a pharmacovigilance study using the WHO's global adverse drug reaction database found disproportionate reporting of eating disorder adverse events with all three major GLP-1 medications ( Nishida et al., Clinical Nutrition, 2025 )